Advancements and applications in radiopharmaceutical therapy.
10.1016/S1875-5364(25)60887-9
- Author:
Shiya WANG
1
;
Mingyi CAO
1
;
Yifei CHEN
1
;
Jingjing LIN
1
;
Jiahao LI
1
;
Xinyu WU
1
;
Zhiyue DAI
1
;
Yuhan PAN
1
;
Xiao LIU
2
;
Xian LIU
3
;
Liang-Ting LIN
3
;
Jianbing WU
1
;
Ji LIU
4
,
5
;
Qifeng ZHONG
6
;
Zhenwei YUAN
7
Author Information
1. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
2. School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, China.
3. Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong 999077, China.
4. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address: jiliu1618@
5. com.
6. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address: zhong@cpu.edu.cn.
7. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address: yuanzhenwei@cpu.edu.cn.
- Publication Type:Review
- Keywords:
Alpha particle nuclide drugs;
BNCT;
Beta particle radionuclide drugs;
Radionuclide therapy;
Radiopharmaceuticals
- MeSH:
Humans;
Radiopharmaceuticals/therapeutic use*;
Neoplasms/radiotherapy*;
Radioisotopes/therapeutic use*;
Animals
- From:
Chinese Journal of Natural Medicines (English Ed.)
2025;23(6):641-657
- CountryChina
- Language:English
-
Abstract:
Radiopharmaceuticals operate by combining radionuclides with carriers. The radiation energy emitted by radionuclides is utilized to selectively irradiate diseased tissues while minimizing damage to healthy tissues. In comparison to external beam radiation therapy, radionuclide drugs demonstrate research potential due to their biological targeting capabilities and reduced normal tissue toxicity. This article reviews the applications and research progress of radiopharmaceuticals in cancer treatment. Several key radionuclides are examined, including 223Ra, 90Y, Lutetium-177 (177Lu), 212Pb, and Actinium-225 (225Ac). It also explores the current development trends of radiopharmaceuticals, encompassing the introduction of novel radionuclides, advancements in imaging technologies, integrated diagnosis and treatment approaches, and equipment-medication combinations. We review the progress in the development of new treatments, such as neutron capture therapy, proton therapy, and heavy ion therapy. Furthermore, we examine the challenges and breakthroughs associated with the clinical translation of radiopharmaceuticals and provide recommendations for the research and development of novel radionuclide drugs.
